Wing morphometrics as a possible tool for the diagnosis of the Ceratitis fasciventris, C. anonae, C. rosa complex (Diptera, Tephritidae)

Por Van Cann, Joannes, Virgilio, Massimiliano, Jordaens, Kurt, De Meyer, Marc
Publicado no Zookeys (2015)

Reconstruction of the alveolar cleft: can growth factor-aided tissue engineering replace autologous bone grafting? A literature review and systematic review of results obtained wit...

Por van Hout, Wouter M. M. T., Mink van der Molen, Aebele B., Breugem, Corstiaan C., Koole, Ronald, Van Cann, Ellen M.
Publicado em 2011

Genetic Basis for the Structural Difference between Streptococcus pneumoniae Serotype 15B and 15C Capsular Polysaccharides

Por van Selm, Saskia, van Cann, Lisette M., Kolkman, Marc A. B., van der Zeijst, Bernard A. M., van Putten, Jos P. M.
Publicado em 2003

Early and late complications in the reconstructed mandible with free fibula flaps

Por van Gemert, Johannes T.M., Abbink, Jan H., van Es, Robert J.J., Rosenberg, Antoine J.W.P., Koole, Ron, Van Cann, Ellen M.
Publicado no J Surg Oncol (2018)

An integrative approach to unravel the Ceratitis FAR (Diptera, Tephritidae) cryptic species complex: a review

Por De Meyer, Marc, Delatte, Hélène, Ekesi, Sunday, Jordaens, Kurt, Kalinová, Blanka, Manrakhan, Aruna, Mwatawala, Maulid, Steck, Gary, Van Cann, Joannes, Vaníčková, Lucie, Břízová, Radka, Virgilio, Massimiliano
Publicado no Zookeys (2015)

Oropharyngeal squamous cell carcinomas differentially express granzyme inhibitors

Por van Kempen, Pauline M. W., Noorlag, Rob, Swartz, Justin E., Bovenschen, Niels, Braunius, Weibel W., Vermeulen, Jeroen F., Van Cann, Ellen M., Grolman, Wilko, Willems, Stefan M.
Publicado no Cancer Immunol Immunother (2016)

Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases

Por Beuselinck, B, Wolter, P, Karadimou, A, Elaidi, R, Dumez, H, Rogiers, A, Van Cann, T, Willems, L, Body, J-J, Berkers, J, Van Poppel, H, Lerut, E, Debruyne, P, Paridaens, R, Schöffski, P
Publicado em 2012

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101...

Por Schöffski, P, Wozniak, A, Stacchiotti, S, Rutkowski, P, Blay, J -Y, Lindner, L H, Strauss, S J, Anthoney, A, Duffaud, F, Richter, S, Grünwald, V, Leahy, M G, Reichardt, P, Sufliarsky, J, van der Graaf, W T, Sciot, R, Debiec-Rychter, M, van Cann, T, Marréaud, S, Lia, M, Raveloarivahy, T, Collette, L, Bauer, S
Publicado no Ann Oncol (2017)

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101...

Por Schöffski, P, Wozniak, A, Stacchiotti, S, Rutkowski, P, Blay, J -Y, Lindner, L H, Strauss, S J, Anthoney, A, Duffaud, F, Richter, S, Grünwald, V, Leahy, M G, Reichardt, P, Sufliarsky, J, van der Graaf, W T, Sciot, R, Debiec-Rychter, M, van Cann, T, Marréaud, S, Lia, M, Raveloarivahy, T, Collette, L, Bauer, S
Publicado no Ann Oncol (2019)